



Ifw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Dieter DORSCH et al.

Examiner: CHENG, Karen

Serial No.: 10/530,876

Group Art Unit: 1626

Filed: April 11, 2005

Title: **HETEROCYCLIC AMIDES AND THEIR USE TREATING THROMBOEMBOLIC DISEASES AND TUMORS**

RESPONSE TO RESTRICTION REQUIREMENT

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement dated October 19, 2006, Applicants hereby elect, with traverse, an alternate embodiment outside of the exemplary groups proposed by the Office Action. Applicants' elected invention encompasses the subject matter of claims 1-15 and 17-20, drawn to compounds of Formula I and/or pharmaceutically usable derivatives, solvates, and stereoisomers thereof, wherein X is NR^3 , R^1 is A which is an unbranched or branched alkyl having 1-10 C atoms, Y is Ar-diyl, D is a thienyl ring which is mono- or disubstituted by Hal, T is morpholin-4-yl which is monosubstituted by carbonyl oxygen (=O), and W is as defined.

In order to comply with the election of species requirement, Applicants further elect (R)-2-[3-(5-chlorothiophen-2-yl)ureido]-N-[4-(3-oxomorpholin-4-yl)-phenyl]-valeramide, as recited in claim 15, and which is the subject matter of Example 1 of the instant application. See, page 27, lines 3-4 of the instant specification.

Withdrawal of this restriction requirement is respectfully requested. The claims in the instant application involve related subject matter, for example, compounds of Formula I, as recited in Applicants' elected Group. A search of all the claims would comprise overlapping subject matter, and it would not be an undue burden on the Examiner to carry out a search. "If search and examination of an entire application can be made without